Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines

Clinical and Diagnostic Laboratory Immunology

Volumn 7, Issue 2, 2000, Pages 145-154

  Asai, Tadao ^a   Storkus, Walter J ^a,b   Whiteside, Theresa L ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD8 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN GP 100; HLA A2 ANTIGEN; IMMUNOLOGICAL ADJUVANT; MELANOMA ANTIGEN; MONOPHENOL MONOOXYGENASE;

ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; IMMUNOASSAY; INTERFERON INDUCTION; MELANOMA; METASTASIS; MONONUCLEAR CELL; PATIENT MONITORING; PRIORITY JOURNAL; STEM CELL; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BIOLOGICAL ASSAY; CANCER VACCINES; CELL LINE; CLINICAL TRIALS; EVALUATION STUDIES; HUMANS; INTERFERON TYPE II; IONOMYCIN; LEUKOCYTES, MONONUCLEAR; MELANOMA; MEMBRANE GLYCOPROTEINS; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTES, CYTOTOXIC; TETRADECANOYLPHORBOL ACETATE; TUMOR CELLS, CULTURED; VACCINES, SYNTHETIC;

EID: 0034091625     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.7.2.145-154.2000     Document Type: Article

References (40)

1. Ahmed, R., and D. Gray. 1996. Immunological memory and protective immunity: understanding their relation. Science 272:54-60.
2. Boon, T., T. F. Gajewski, and P. G. Coulie. 1995. From defined human tumor antigens to effective immunization. Immunol. Today 16:334-336.
3. Carmichael, A., X. Jin, P. Sissons, and L. Borysiewicz. 1993. Quantitative analysis of the HIV-1-specific CTL response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J. Exp. Med. 177:249-256.
4. Coulie, P., M. Somville, F. Lehmann, P. Hainaut, F. Brasseur, R. Devos, and T. Boon. 1992. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int. J. Cancer 50:289-297.
5. Czerkinsky, C., G. Anderson, H.-P. Ekre, L.-A. Nilsson, L. Klareskog, and O. Ouchterlony. 1988. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J. Immunol. Methods 110:29-36.
6. + T cells. Science 280:227.
7. Fujihashi, K., J. R. McGhee, K. W. Beagley, D. T. Mcpherson, S. A. Mcpherson, C. M. Huang, and H. Kiyono. 1993. Cytokine-specific ELISPOT assay. Single cell analysis of IL-2, IL-4 and IL-6 producing cells. J. Immunol. Methods 160:181-189.
8. Heo, D. S., C. H. Snyderman, S. M. Gollin, S. Pan, E. Walker, R. Deka, E. L. Barnes, J. T. Johnson, R. B. Herberman, and T. L. Whiteside. 1989. Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. Cancer Res. 49:5167-5175.
9. + T lymphocytes producing tumor necrosis factor a spots in response to peptide antigens. J. Immunol. Methods 203:141-151.
10. Herr, W., J. Schneider, L. W. Ansgar, K.-H. Meyer Zum Buschenfelde, and T. Wolfel. 1996. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor a in response to HLA-A2.1-binding melanoma and viral peptide antigens. J. Immunol. Methods 191: 131-142.
11. Herr, W., T. Wolfel, M. Heike, K.-H. Meyer Zum Buschenfelde, and A. Knuth. 1994. Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells. Cancer Immunol. Immunother. 39:93-99.
12. Jager, E., H. Bernhard, P. Romero, M. Ringhoffer, M. Arand, J. Karbach, C. Ilsemann, M. Hagedorn, and A. Knuth. 1996. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int. J. Cancer 66: 162-169.
13. Kabilan, L., G. Andersson, F. Lolli, H.-P. Ekre, T. Olsson, and M. Troye-Blomberg. 1990. Detection of intra-cellular expression and secretion of interferon-γ at the single-cell level after activation of human T cells with tetanus toxoid in vitro. Lur. J. Immunol 20:1085-1089.
14. Klinman, D. M. 1994. ELISPOT assay to detect cytokine-secreting murine and human cells. Curr. Protocols Immunol. 19:1-8.
15. + memory T cells. J. Exp. Med. 186:859-864.
16. Marchand, M., P. Weynants, E. Rankin, F. Arienti, F. Belli, G. Parmiani, N. Cascinelli, A. Bourlond, R. Vanwijck, Y. Humblet, J.-L. Canon, C. Laurent, J.-M. Naeyaert, R. Plagne, R. Deraemaeker, A. Knuth, E. Jager, F. Brasseur, J. Herman, P. G. Coulie, and T. Boon. 1995. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer 63:883-885.
17. Miescher, S., T. L. Whiteside, L. Moretta, and V. Von Fliedner. 1987. Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. J. Immunol. 138:4004-4011.
18. + T cells using an ELISPOT assay. J. Immunol. Methods 181:45-54.
19. Morris, A. G., Y. L. Lin, and B. A. Askonas. 1982. Immune interferon release when a cloned cytotoxic T cell line meets its correct influenza-infected target cell. Nature 295:150-152.
20. Nordstrom, L., and B. Ferrua. 1992. Reverse elispot assay for clonal analysis of cytokine production. II. Enumeration of interleukin-1-secreting cells by amplified (avidin-biotin antiperoxidase) assay. J. Immunol. Methods 150:199-206.
21. + T lymphocytes and human squamous cell carcinoma of the head and neck. Cell. Immunol. 177:35-48.
22. Pass, H. A., S. L. Schwarz, J. E. Wunderlich, and S. A. Rosenberg. 1998. Immunization of patients with melanoma peptide vaccines: immunologic assessment using ELISPOT assay. Cancer J. Sci. Am. 4:316-323.
23. Rivoltini, L., D. J. Loftus, P. Squarcina, C. Castelli, F. Rini, F. Arienti, F. Belli, F. M. Marincola, C. Geisler, A. Borsatti, E. Appella, and G. Parmiani. 1998. Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in downregulating anti-tumor T-cell reactivity. Crit. Rev. Immunol. 18:55-63.
24. Romero, P., J.-C. Ccrottini, and G. Waanders. 1998. Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy. Mol. Med. Today 4:305-312.
25. Ronnelid, J., and L. Klareskog. 1997. A comparison between ELISPOT methods for the detection of cytokine producing cells: grated sensitivity and specificity using ELISA plates as compared to nitrocellulose membranes. J. Immunol. Methods 20:17-26.
26. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. M. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, J. R. Wunderlich, M. R. Parkhurst, Y. Kawakami, C. A. Seipp, J. H. Einhorn, and D. E. White. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321-327.
27. Rotzschke, O., K. Falk, K. Deres, H. Schild, M. Norda, J. Metzger, G. Jung, and H. G. Rammensee. 1990. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 348:252-254.
28. + T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin. Cancer Res. 3:221-226.
29. Scheibenbogen, C., K.-H. Lee, S. Stevanovic, M. Witzens, M. Willhauck, V. Waldmann, H. Naeher, H.-G. Rammensee, and U. Keilholz. 1997. Analysis of the T-cell response to tumor and viral peptide antigens by an IFN-γ-ELISPOT assay. Int. J. Cancer 71:1-5.
30. Shimizu, Y., S. Iwatsuki, R. B. Herberman, and T. L. Whiteside. 1990. Clonal analysis of tumor-infiltrating lymphocytes from human primary and metastatic liver tumors. Int. J. Cancer 46:878-993.
31. Tanguay, S., and J. Killion. 1994. Direct comparison of ELISPOT and ELISA-based assays for detection of individual cytokine-secreting cells. Lymphokine Cytokine Res. 13:259-263.
32. Taswell, C. 1981. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J. Immunol. 126:614-619.
33. Van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. de Plaen, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647.
34. Van der Eynde, B., and P. van der Bruggen. 1997. T-cell defined tumor antigens. Curr. Opin. Immunol. 9:684-693.
35. Whiteside, T. L., J. Bryant, R. Day, and R. B. Herberman. Natural killer cytotoxicity in the diagnosis of immune dysfunction: criteria for a reproducible assay. J. Clin. Lab. Anal. 4:102-114.
36. Whiteside, T. L., K. Chikamatsu, S. Nagashima, and K. Okada. 1996. Antitumor effects of cytolytic T lymphocytes (CTL) and natural killer (NK) cells in head and neck cancer. Anticancer Res. 16:2357-2364.
37. Whiteside, T. L., S. Miescher, J. Hurlimann, and V. von Fliedner. 1986. Separation, phenotyping and limiting-dilution analysis of T-lymphocytes infiltrating human solid tumors. Int. J. Cancer 37:803-811.
38. Whiteside, T. L., and H. Rabinowich. 1998. The role of Fas/FasL in immunosuppression induced. by human tumors. Cancer Immunol. Immunother. 46:175-184.
39. Whiteside, T. L., M.-W. Sung, S. Nagashima, K. Chikamatsu, K. Okada, and N. L. Vujanovic. 1998. Human tumor antigen-specific T lymphocytes and IL2-activated natural killer (A-NK) cells: comparisons of antitumor effects in vitro and in vivo. Clin. Cancer Res. 4:1135-1145.
40. Wolfel, T., A. van Pel, V. Brichard, J. Schneider, B. Selinger, K. H. Meyer zum Buschenfelde, and T. Boon. 1994. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol. 24:759-764.